Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs (Q44303787)

1 December 2017

Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs (English)

1 reference

1 December 2017

0 references

0 references

7

Alan D Cherrington

1 reference

1 December 2017

Mary E. Courtney Moore

2

object named as

Mary Courtney Moore

1 reference

1 December 2017

6

Doss W Neal

1 reference

1 December 2017

Makoto Nishizawa

1

1 reference

1 December 2017

Masakazu Shiota

3

1 reference

1 December 2017

Stephanie M Gustavson

4

1 reference

1 December 2017

Wanda L Snead

5

1 reference

1 December 2017

4 February 2003

1 reference

American Journal of Physiology - Endocrinology and Metabolism

1 December 2017

1 reference

1 December 2017

284

1 reference

1 December 2017

5

1 reference

1 December 2017

E1027-36

1 reference

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 December 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Comparison of the direct and indirect effects of epinephrine on hepatic glucose production

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

The HISS story overview: a novel hepatic neurohumoral regulation of peripheral insulin sensitivity in health and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Direct and indirect effects of insulin on glucose uptake and storage by the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Glucagon-like peptide 1: a potent glycogenic hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

GLP-1 does not acutely affect insulin sensitivity in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00503.2002

10.1152/AJPENDO.00503.2002

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference